LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Home・Elenco Azioni・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

84.4 -3.55

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

82.74

Massimo

87.35

Metriche Chiave
By Trading Economics
Entrata	-8.1M -56M
Vendite	2.9M 60M
EPS	-0.83
Margine di Profitto	-92.559
Dipendenti	414
EBITDA	-9.7M -52M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+55.65% upside

Dividendi
By Dow Jones
Utili prossimi	4 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-96M 5.8B
Apertura precedente	87.95
Chiusura precedente	84.4

Notizie sul Sentiment di mercato

By Acuity

60%

40%

270 / 344 Classifica in Healthcare

Rhythm Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

2 giu 2026, 20:30 UTC

Utili

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2 giu 2026, 23:58 UTC

Discorsi di Mercato

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2 giu 2026, 23:46 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

2 giu 2026, 23:46 UTC

Discorsi di Mercato

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2 giu 2026, 23:41 UTC

Discorsi di Mercato

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2 giu 2026, 23:01 UTC

Acquisizioni, Fusioni, Takeovers

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2 giu 2026, 23:01 UTC

Acquisizioni, Fusioni, Takeovers

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2 giu 2026, 23:00 UTC

Acquisizioni, Fusioni, Takeovers

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2 giu 2026, 22:57 UTC

Discorsi di Mercato

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2 giu 2026, 22:50 UTC

Discorsi di Mercato

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2 giu 2026, 21:07 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

2 giu 2026, 21:07 UTC

Discorsi di Mercato

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2 giu 2026, 21:00 UTC

Utili

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 giu 2026, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

2 giu 2026, 20:46 UTC

Utili

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 giu 2026, 20:38 UTC

Utili

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2 giu 2026, 20:21 UTC

Utili

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 giu 2026, 20:12 UTC

Utili

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks 3Q Product Rev $594M

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks 3Q Adj EPS 85c >PANW

2 giu 2026, 20:05 UTC

Utili

Palo Alto Networks 3Q Loss $177M >PANW

Confronto tra pari

Modifica del prezzo

Rhythm Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

55.65% in crescita

Previsioni per 12 mesi

Media 136.77 USD 55.65%

Alto 158 USD

Basso 105 USD

Basato su 14 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Rhythm Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

14 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 14 che hanno fornito valutazioni azionarie a Rhythm Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

270 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.